BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 17679815)

  • 1. Polycystic ovarian syndrome.
    Khan KA; Stas S; Kurukulasuriya LR
    J Cardiometab Syndr; 2006; 1(2):125-30; quiz 131-2. PubMed ID: 17679815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
    Spritzer PM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk in women with polycystic ovary syndrome.
    Giallauria F; Orio F; Palomba S; Lombardi G; Colao A; Vigorito C
    J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):987-92. PubMed ID: 18799960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome. Long term sequelae and management.
    Legro RS
    Minerva Ginecol; 2002 Apr; 54(2):97-114. PubMed ID: 12032449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG; Patchava S; Laing I
    Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiometabolic risks in PCOS: a review of the current state of knowledge.
    Kakoly NS; Moran LJ; Teede HJ; Joham AE
    Expert Rev Endocrinol Metab; 2019 Jan; 14(1):23-33. PubMed ID: 30556433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-sensitisers in the treatment of polycystic ovary syndrome.
    Teede HJ; Meyer C; Norman RJ
    Expert Opin Pharmacother; 2005 Nov; 6(14):2419-27. PubMed ID: 16259573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic biomarkers in women with polycystic ovary syndrome.
    van der Ham K; Louwers YV; Laven JSE
    Fertil Steril; 2022 May; 117(5):887-896. PubMed ID: 35512973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
    Osibogun O; Ogunmoroti O; Michos ED
    Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the PCOS phenotype with age.
    Hsu MI
    Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polycystic ovarian disease. 1. The current data on its etiology and pathogenesis].
    Rachev E
    Akush Ginekol (Sofiia); 1999; 38(2):42-5. PubMed ID: 10730388
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
    Mayer SB; Evans WS; Nestler JE
    Womens Health (Lond); 2015 Mar; 11(2):137-49. PubMed ID: 25776288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural, biochemical and non-traditional cardiovascular risk markers in PCOS.
    Christakou C; Diamanti-Kandarakis E
    Curr Pharm Des; 2013; 19(32):5764-74. PubMed ID: 23448483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
    Svendsen PF; Nilas L; Nørgaard K; Madsbad S
    Ugeskr Laeger; 2005 Aug; 167(34):3147-51. PubMed ID: 16117910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.